Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes

OBJECTIVE: Until recently, riluzole was the only drug licensed for amyotrophic lateral sclerosis (ALS). In spite of its efficacy, the mechanism of action remains elusive, and both blocking of glutamate release and antioxidant properties have been postulated. Here we characterized human SH-SY5Y neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sala, Gessica, Arosio, Alessandro, Conti, Elisa, Beretta, Simone, Lunetta, Christian, Riva, Nilo, Ferrarese, Carlo, Tremolizzo, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705104/
https://www.ncbi.nlm.nih.gov/pubmed/31352711
http://dx.doi.org/10.9758/cpn.2019.17.3.438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705104/
https://www.ncbi.nlm.nih.gov/pubmed/31352711
http://dx.doi.org/10.9758/cpn.2019.17.3.438

Ejemplares similares